← Human Trials & Peer-Reviewed Studies
Association of semaglutide treatment with coronary artery inflammation in type 2 diabetes mellitus patients: a retrospective study based on pericoronary adipose tissue attenuation
Plain-language guide to PMID 39342279 (2024): observational study of Semaglutide in 497 patients.
Key Facts
- PMID
- 39342279
- Journal
- Cardiovascular diabetology
- Year
- 2024
- Study type
- Observational Study
- Authors
- Li Y et al. (8 authors)
- DOI
- 10.1186/s12933-024-02445-2
What This Study Did, in Plain Language
What Was Tested
This observational study looks at Semaglutide.
This study aimed to investigate the association between semaglutide treatment and coronary artery inflammation based on FAI in patients with type 2 diabetes mellitus (T2DM).
Why It Was Studied
The pericoronary fat attenuation index (FAI) has emerged as a novel and sensitive biomarker reflecting the degree of coronary artery inflammation.
Who Took Part
The study group was 497 patients.
PubMed indexes the participants as middle-aged adults and older adults, both men and women.
This study enrolled 497 T2DM patients who underwent coronary computed tomography angiography (CCTA) at Hebei General Hospital, of whom 93 treated with semaglutide (Sema+) and 404 did not (Sema-).
Multivariate linear regression models were used to analyze the association between semaglutide treatment and pericoronary FAI.
How the Study Was Run
Clinical data, laboratory indicators, and CCTA parameters were collected and compared between the two groups at baseline.
Propensity score matching (PSM) was used to adjust for confounders, and pericoronary FAI was compared.
What Was Measured
The subject headings attached to it are Diabetes Mellitus, Type 2, Coronary Artery Disease, Hypoglycemic Agents, Glucagon-Like Peptides, Coronary Angiography, Computed Tomography Angiography and Adiposity.
Author keywords: Pericoronary adipose tissue, Semaglutide, Type 2 diabetes mellitus and Vascular inflammation.
What This Means in Plain Language
This is an observational study of Semaglutide in 497 patients.
With several hundred people or more, it is a fairly large study for this kind of research.
Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2024 (Cardiovascular diabetology), a journal based in England.
More context: the Semaglutide compound page, all human trials.
Our Notes on the Compound
Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.